PE20191783A1 - Moleculas probioticas para reducir virulencia patogena - Google Patents

Moleculas probioticas para reducir virulencia patogena

Info

Publication number
PE20191783A1
PE20191783A1 PE2019001882A PE2019001882A PE20191783A1 PE 20191783 A1 PE20191783 A1 PE 20191783A1 PE 2019001882 A PE2019001882 A PE 2019001882A PE 2019001882 A PE2019001882 A PE 2019001882A PE 20191783 A1 PE20191783 A1 PE 20191783A1
Authority
PE
Peru
Prior art keywords
probiotic molecules
reduce pathogenic
probiotic
virulence
pathogenic virulence
Prior art date
Application number
PE2019001882A
Other languages
English (en)
Inventor
Monica Angela Cella
Sarah M Curtis
Jonathon Patrick Roepke
Original Assignee
Microsintesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microsintesis Inc filed Critical Microsintesis Inc
Publication of PE20191783A1 publication Critical patent/PE20191783A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Referido a un peptido derivado de bacterias probioticas, tales como Lactobacillus, Lactococcus, entre otros. Estos peptidos son utiles para prevenir y/o tratar una infeccion no enterica, y para reducir su virulencia. Ademas, estas moleculas probioticas se combinan con uno o mas antivirales, una fuente de azucar, productos alimenticios, bebidas, suplementos nutricionales, medicamentos y similares.
PE2019001882A 2017-03-16 2018-03-16 Moleculas probioticas para reducir virulencia patogena PE20191783A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472061P 2017-03-16 2017-03-16
PCT/CA2018/050320 WO2018165765A1 (en) 2017-03-16 2018-03-16 Propiotic molecules for reducing pathogen virulence

Publications (1)

Publication Number Publication Date
PE20191783A1 true PE20191783A1 (es) 2019-12-24

Family

ID=63521745

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001882A PE20191783A1 (es) 2017-03-16 2018-03-16 Moleculas probioticas para reducir virulencia patogena

Country Status (16)

Country Link
US (2) US11912788B2 (es)
EP (1) EP3595698A4 (es)
JP (2) JP2020510096A (es)
KR (2) KR20190140443A (es)
CN (1) CN110621332A (es)
AU (2) AU2018233183A1 (es)
BR (1) BR112019019256A2 (es)
CA (1) CA3056719A1 (es)
CL (1) CL2019002640A1 (es)
EA (1) EA201992176A1 (es)
MA (1) MA51873A (es)
MX (1) MX2019011058A (es)
PE (1) PE20191783A1 (es)
PH (1) PH12019502340A1 (es)
SG (1) SG11201909606RA (es)
WO (1) WO2018165765A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018233183A1 (en) 2017-03-16 2019-10-31 Microsintesis Inc. Probiotic molecules for reducing pathogen virulence
CA3056718A1 (en) * 2017-03-16 2018-09-20 Microsintesis Inc. Compositions and methods involving probiotic molecules
WO2021000046A1 (en) * 2019-07-02 2021-01-07 Microsintesis Inc. Quorum-sensing inhibitors and/or postbiotic metabolites and related methods
CN115039885B (zh) * 2021-05-14 2023-11-03 江苏艾兰得营养品有限公司 一种具有抑制奇异变形杆菌生长作用的副干酪乳杆菌及其益生菌组合物、发酵液和应用
CA3150903A1 (en) * 2021-05-14 2022-11-14 Xuejun Li Probiotic for inhibiting growth of proteus mirabilis, and fermentation broth and application thereof
KR102337951B1 (ko) * 2021-06-25 2021-12-13 주식회사 비피도 요로감염 개선, 예방 또는 치료를 위한 락토바실러스 헬베티쿠스 gut10 균주 및 이를 포함하는 조성물
KR102356423B1 (ko) * 2021-07-02 2022-02-09 (주)에스디생명공학 항균, 피부 보습, 항아토피, 피부 장벽 강화, 및 주름 개선 활성을 갖는 복합 균주를 유효성분으로 포함하는 조성물
KR102618322B1 (ko) * 2021-10-08 2023-12-27 순천향대학교 산학협력단 신규한 락토 바실러스 균주, 및 이를 포함하는 결핵 예방, 치료, 또는 개선용 조성물
CN114106096A (zh) * 2021-11-16 2022-03-01 华南理工大学 一种具有改善睡眠活性的六肽及其应用
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
KR102551065B1 (ko) * 2022-05-12 2023-07-03 중앙대학교 산학협력단 김치로부터 유래된 LAB(lactic acid bacteria)을 유효성분으로 포함하는 항-바이오필름 조성물
CN116478882A (zh) * 2023-05-05 2023-07-25 石河子大学 能够提高绵羊日增重和饲料转化率的产酸的混合菌制剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395309B1 (en) 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
FR2686085B1 (fr) 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
WO1994018832A1 (en) 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2004092206A1 (ja) 2003-04-14 2004-10-28 Meiji Dairies Corporation 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
DE10317870A1 (de) * 2003-04-17 2004-11-04 Crompton Vinyl Additives Gmbh Neues Stabilisatorsystem zur Stabilisierung von halogenhaltigen Polymeren
JP2007518400A (ja) * 2003-12-04 2007-07-12 バイオフィルムズ ストラテジーズ， インコーポレイテッド バイオフィルムの形成を防止、存在するバイオフィルムを減少、および細菌の個体群を減少させるための方法ならびに組成物
US7306677B2 (en) * 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
WO2006068480A2 (en) 2004-12-23 2006-06-29 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use
JP2009516738A (ja) * 2005-11-21 2009-04-23 ティーガスク−ザ アグリカルチャー アンド フード デベロップメント オーソリティー カゼイン由来の抗菌ペプチドおよびそれを生成するＬａｃｔｏｂａｃｉｌｌｕｓ株
US8431528B2 (en) 2008-05-16 2013-04-30 University Of Maryland, Baltimore Antibacterial Lactobacillus GG peptides and methods of use
CA2765298A1 (en) 2008-06-27 2009-12-30 University Of Guelph Probiotic bacterial molecules and their use in methods to treat/prevent infection by harmful bacteria and to provide nutritional health
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
PT105073A (pt) 2010-04-26 2011-10-26 Consejo Superior Investigacion Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações
WO2014020209A1 (es) 2012-07-30 2014-02-06 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de proteínas lácteas como protectores a nivel gastrointestinal
US9273096B2 (en) * 2012-08-29 2016-03-01 Agency For Science, Technology And Research Amphiphilic peptides comprising the formula I: (X1Y1X2Y2)n, and uses thereof
EP2890706A1 (en) 2012-08-31 2015-07-08 Westfälische Wilhelms-Universität Münster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
WO2015021530A1 (en) 2013-08-12 2015-02-19 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
SG11201603234WA (en) * 2013-10-31 2016-05-30 Hutchison Biofilm Medical Solutions Ltd Use of peptides in antibiotic resistance
CN108513593A (zh) 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
CA3056718A1 (en) 2017-03-16 2018-09-20 Microsintesis Inc. Compositions and methods involving probiotic molecules
AU2018233183A1 (en) 2017-03-16 2019-10-31 Microsintesis Inc. Probiotic molecules for reducing pathogen virulence

Also Published As

Publication number Publication date
JP2020510096A (ja) 2020-04-02
US20200017547A1 (en) 2020-01-16
CL2019002640A1 (es) 2020-05-15
AU2022203650B2 (en) 2024-04-11
MA51873A (fr) 2020-01-22
CN110621332A (zh) 2019-12-27
KR20240046640A (ko) 2024-04-09
MX2019011058A (es) 2019-12-09
CA3056719A1 (en) 2018-09-20
JP2023036938A (ja) 2023-03-14
EA201992176A1 (ru) 2020-03-04
EP3595698A1 (en) 2020-01-22
US11912788B2 (en) 2024-02-27
BR112019019256A2 (pt) 2020-04-14
US20240150399A1 (en) 2024-05-09
WO2018165765A1 (en) 2018-09-20
PH12019502340A1 (en) 2020-10-19
SG11201909606RA (en) 2019-11-28
KR20190140443A (ko) 2019-12-19
WO2018165765A9 (en) 2018-11-22
AU2018233183A1 (en) 2019-10-31
AU2022203650A1 (en) 2022-06-16
EP3595698A4 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
PE20191783A1 (es) Moleculas probioticas para reducir virulencia patogena
PE20191785A1 (es) Composiciones y metodos que involucran moleculas probioticas
MX350325B (es) Bacteria para usarse como un probiotico para aplicaciones nutricionales y medicas.
EA201391500A1 (ru) Синергический противомикробный эффект
MY187060A (en) Bifidobacteria as probiotic foundation species of gut microbiota
MY197201A (en) Novel probiotics bifidobacteria strains
EA201890223A1 (ru) Lactobacillus paracasei для продуцирования линолевой кислоты с сопряженными связями, питательные и фармацевтические препараты, содержащие этот штамм, и их применение
BR112017010475A2 (pt) cepas de lactobacillus ou bifidobacterium para manter homeostase
BRPI1010637A2 (pt) suplementos nutricionais orais compreendendo probióticos
MX2021016034A (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella.
MX2015012379A (es) Novedosas cepas de lactobacillus y los usos de las mismas.
BR112017012251A2 (pt) cepas probióticas que têm capacidade absorvente de colesterol, métodos e usos das mesmas
BR112017014649A2 (pt) ?isolado intestinal humano, e, composição?
SG11201804006QA (en) Novel peptide
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
PH12017502042A1 (en) Dietary supplement
BR112015028164A2 (pt) probióticos e métodos de uso
RU2012102851A (ru) Штамм enterococcus durans вкпм в-8731, используемый для производства кисломолочных продуктов и пробиотических препаратов
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
MX2015010694A (es) Peptidos funcionales para trastornos de obesidad.
MX2017005136A (es) Producto lacteo fermentado cavitado.
MX2018007780A (es) Composiciones y metodos de uso de cepas novedosas de lactobacillus fermentum.
AR089034A1 (es) Lactobacillus brevis productor de reuterina
MX2020001501A (es) Streptococcus australis como bioterapeuticos.
MX371444B (es) Metodo para inducir saciedad.